Skip to main content

Table 1 Subgroup analysis for the efficacy of serum miRNA in the diagnosis of total NAFLD

From: Efficacy of serum miRNA test as a non-invasive method to diagnose nonalcoholic steatohepatitis: a systematic review and meta-analysis

Study factors Subgroups Case (n) Sensitivity (95% CI) I2 (%) Specificity (95% CI) I2 (%) PLR (95% CI) NLR (95% CI) DOR (95% CI) AUROC (95% CI)
Geographic region Asian 11 0.64 (0.49, 0.77) 96.08 0.76 (0.65, 0.85) 92.08 2.7 (1.9, 3.7) 0.47 (0.34, 0.65) 6 (3, 9) 0.77 (0.73, 0.80)
Non-Asian 16 0.77 (0.71, 0.83) 81.33 0.83 (0.76, 0.88) 76.03 4.5 (3.2, 6.5) 0.27 (0.20, 0.37) 17 (9, 30) 0.87 (0.84, 0.90)
Type of disease NASH 13 0.74 (0.66, 0.81) 74.94 0.85 (0.77, 0.91) 79.60 5.0 (3.1, 8.0) 0.31 (0.23, 0.42) 16 (8, 32) 0.86 (0.83, 0.89)
NAFLD 14 0.71 (0.58, 0.81) 96.88 0.76 (0.68, 0.83) 90.57 3.0 (2.2, 4.0) 0.38 (0.26, 0.55) 8 (5, 13) 0.80 (0.77, 0.84)
Regulation mode Upregulation 21 0.74 (0.65, 0.81) 95.92 0.78 (0.71, 0.83) 90.07 3.4 (2.5, 4.6) 0.33 (0.24, 0.46) 10 (6, 17) 0.83 (0.80, 0.86)
Downregulation 6 0.66 (0.56, 0.74) 59.82 0.89 (0.79, 0.95) 58.87 6.0 (3.2, 11.5) 0.38 (0.30, 0.49) 16 (8, 31) 0.83 (0.79, 0.86)
Proportion of males ≥ 50% 12 0.64 (0.50, 0.76) 95.58 0.74 (0.63, 0.82) 90.78 2.4 (1.8, 3.2) 0.49 (0.37, 0.65) 5 (3, 8) 0.75 (0.71, 0.79)
<  50% 9 0.77 (0.66, 0.85) 81.17 0.87 (0.76, 0.93) 58.46 5.7 (3.3, 10.0) 0.27 (0.19, 0.39) 21 (11, 31) 0.89 (0.86, 0.90)
BMI ≥ 30 kg/m2 15 0.77 (0.69, 0.83) 82.34 0.84 (0.76, 0.89) 76.67 4.7 (3.2, 6.9) 0.28 (0.20, 0.38) 17 (9, 31) 0.87 (0.84, 0.90)
< 30 kg/m2 9 0.63 (0.45, 0.78) 96.69 0.75 (0.61, 0.85) 93.11 2.5 (1.8, 3.6) 0.49 (0.34, 0.71) 5 (3, 9) 0.76 (0.72, 0.79)
  1. AUROC area under the receiver operating characteristic curve, CI confidence interval, DOR diagnostic odds ratio, NAFLD nonalcoholic fatty liver disease, NASH nonalcoholic steatohepatitis, NLR negative likelihood ratio, PLR positive likelihood ratio